Kolexia
Perdrix Anne
Biologie médicale
Centre Henri-Becquerel
Rouen, France
61 Activités
0 Followers

Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Métastase tumorale Cellules tumorales circulantes Infertilité masculine Tumeurs colorectales Azoospermie Cancers du sein inflammatoires Tumeurs embryonnaires et germinales Infertilité

Industries

Pfizer
1 collaboration(s)
Dernière en 2021
{{person.topindus2.name}}
{{person.topindus2.tot}} collaboration(s)
Dernière en {{person.topindus2.last}}
{{person.topindus3.name}}
{{person.topindus3.tot}} collaboration(s)
Dernière en {{person.topindus3.last}}
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Clinical relevance of circulating ESR1 mutations during endocrine therapy for advanced hormone-dependent endometrial carcinoma.
BMC cancer   03 novembre 2023
Cardiovascular outcomes of patients treated for non-Hodgkin lymphoma with first-line doxorubicin-based chemotherapy.
Leukemia & lymphoma   18 septembre 2022
Diagnostic and predictive accuracy of anti-mullerian hormone for ovarian function after chemotherapy in premenopausal women with early breast cancer.
Breast cancer research and treatment   08 janvier 2022
Circulating PIK3CA mutation detection at diagnosis in non-metastatic inflammatory breast cancer patients.
Scientific reports   15 décembre 2021
CEA, CA19-9, circulating DNA and circulating tumour cell kinetics in patients treated for metastatic colorectal cancer (mCRC).
British journal of cancer   10 juin 2021
Use of a high-sensitivity anti-Mullerian hormone (AMH) assay to determine ovarian function after chemotherapy for early breast cancer.
2021 ASCO Annual Meeting I   28 mai 2021
265P Circulating PIK3CA mutation detection at diagnosis in non-metastatic inflammatory breast cancer patients
Abstract Book of the ESMO Virtual Congress2020 19 – 21 September / 16 – 18 October 2020   01 septembre 2020
FMER: Determination of ESR1 Mutations by Digital PCR During Aromatase Inhibitor Treatment in Metastatic Breast Cancer
Essai Clinique (Centre Henri-Becquerel)   29 juillet 2020
Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer.
Breast cancer research : BCR   28 mai 2020
Postoperative hunger after outpatient surgery in patients anesthetized with propofol vs sevoflurane: a randomized-controlled trial.
Canadian journal of anaesthesia = Journal canadien d'anesthesie   29 janvier 2020